vTv Therapeutics ( (VTVT) ) has issued an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending the development of the ppar-δ agonist program. This move, effective January 2025, might impact investors interested in the pharmaceutical collaborations and the future of vTv’s intellectual property ventures.
Learn more about VTVT stock on TipRanks’ Stock Analysis page.